Tag: PAA

PharmAust ASX PAA University of Melbourne U-Vet Werribee Animal Hospital Phase 2 clinical trial monepantel cancer

PharmAust and U-Vet gear up for Phase 2 clinical trial of leading drug candidate monepantel

Oncology company PharmAust (ASX: PAA) is on the home straight to commencing a milestone drug trial following the finalisation of contractual arrangements for its Phase 2...
PharmAust ASX PAA Monepantel tablets Phase 1 dogs

PharmAust reports positive results from phase I anti-cancer tablet trial on dogs

Clinical-stage oncology company PharmAust (ASX: PAA) has received early positive results from a phase I trial of its reformulated monepantel anti-cancer tablets. The canine-based trial...
PharmAust ASX PAA monepantel clinical trials humans canine dog anti-cancer tablet

PharmAust to begin anti-cancer tablet trials in dogs this month

Oncology company PharmAust (ASX: PAA) has manufactured its first batch of monepantel anti-cancer tablets in readiness for the phase I clinical trial in dogs,...
PharmAust ASX PAA principal metabolite anti cancer properties monepantel

PharmAust’s principal metabolite confirmed to have anti-cancer properties

Oncology company PharmAust (ASX: PAA) has revealed positive news in relation to its ongoing development of monepantel, with the company confirming that monepantel’s major metabolite...
PharmAust ASX PAA upscale cancer drug candidate Monepantel Syngene International

PharmAust readies to upscale its flagship cancer drug candidate Monepantel

Clinical-stage oncology company PharmAust (ASX: PAA) could be set to upscale development of its flagship drug candidate ‘Monepantel’, a cancer drug that is potentially...
PharmAust ASX PAA treat cancer dogs oncology

PharmAust targets unique market for treating cancer in dogs

Australian vets and dog-lovers could soon have an additional weapon in their toolkit to treat cancer in dogs, courtesy of a novel therapy to...
PharmAust ASX PAA secures US patent cancer drugs

PharmAust secures US patent for cancer drugs

PharmAust (ASX: PAA) has locked in a US patent for its aminoacetonitrile compound drug portfolio, which have anti-cancer properties. “Allowance of this patent secures PharmAust’s...